Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 488 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib April 28, 2023 FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer... January 10, 2025 Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC May 15, 2023 DNA from Ancient Viruses Helps Many Cancers Grow September 6, 2024 Load more HOT NEWS Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response COVID-19 Takes the Life of a Widowed Mother of 6 Who...
